| # | Title | Journal | Year | Citations |
|---|
| 1 | Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections | Core Evidence | 2014 | 142 |
| 2 | Luliconazole for the treatment of fungal infections: an evidence-based review | Core Evidence | 2014 | 78 |
| 3 | Sugammadex as a reversal agent for neuromuscular block: an evidence-based review | Core Evidence | 2013 | 75 |
| 4 | An evidence-based review of obatoclax mesylate in the treatment of hematological malignancies | Core Evidence | 2013 | 63 |
| 5 | Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy | Core Evidence | 2016 | 61 |
| 6 | Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes | Core Evidence | 2011 | 59 |
| 7 | An evidence-based review of linezolid for the treatment of methicillin-resistant Staphylococcus aureus (MRSA): place in therapy | Core Evidence | 2012 | 53 |
| 8 | Clinical utility of patiromer, sodium zirconium cyclosilicate, and sodium polystyrene sulfonate for the treatment of hyperkalemia: an evidence-based review | Core Evidence | 2017 | 50 |
| 9 | <p>Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapy</p> | Core Evidence | 2019 | 50 |
| 10 | Sipuleucel-T in the treatment of prostate cancer: an evidence-based review of its place in therapy | Core Evidence | 2015 | 48 |
| 11 | Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy | Core Evidence | 2016 | 45 |
| 12 | Efficacy of palifermin (keratinocyte growth factor-1) in the amelioration of oral mucositis | Core Evidence | 2010 | 42 |
| 13 | Pancrelipase: an evidence-based review of its use for treating pancreatic exocrine insufficiency | Core Evidence | 2012 | 42 |
| 14 | Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma | Core Evidence | 2011 | 41 |
| 15 | Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis | Core Evidence | 2018 | 41 |
| 16 | Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-positive glioblastoma | Core Evidence | 2012 | 39 |
| 17 | <p>Lomitapide: a review of its clinical use, efficacy, and tolerability</p> | Core Evidence | 2019 | 39 |
| 18 | Targeted therapy in triple-negative metastatic breast cancer: a systematic review and meta-analysis | Core Evidence | 2014 | 36 |
| 19 | Fosaprepitant and aprepitant: an update of the evidence for their place in the prevention of chemotherapy-induced nausea and vomiting | Core Evidence | 2010 | 34 |
| 20 | Dapoxetine: an evidence-based review of its effectiveness in treatment of premature ejaculation | Core Evidence | 2012 | 33 |
| 21 | Mipomersen: evidence-based review of its potential in the treatment of homozygous and severe heterozygous familial hypercholesterolemia | Core Evidence | 2012 | 32 |
| 22 | Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review | Core Evidence | 2010 | 29 |
| 23 | Rasburicase in the management of tumor lysis: an evidence-based review of its place in therapy | Core Evidence | 2015 | 29 |
| 24 | Golimumab: A novel human anti-TNF-α monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis | Core Evidence | 2010 | 27 |
| 25 | Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas | Core Evidence | 2009 | 25 |
| 26 | Agomelatine: The evidence for its place in the treatment of depression | Core Evidence | 2010 | 24 |
| 27 | Aztreonam (for inhalation solution) for the treatment of chronic lung infections in patients with cystic fibrosis: an evidence-based review | Core Evidence | 2011 | 24 |
| 28 | An evidence-based review of the potential benefits of taliglucerase alfa in the treatment of patients with Gaucher disease | Core Evidence | 2012 | 24 |
| 29 | Saxagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus | Core Evidence | 2010 | 22 |
| 30 | Enzalutamide: an evidence-based review of its use in the treatment of prostate cancer | Core Evidence | 2013 | 22 |
| 31 | Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy | Core Evidence | 2014 | 22 |
| 32 | Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis | Core Evidence | 2015 | 22 |
| 33 | Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review | Core Evidence | 2015 | 22 |
| 34 | Brodalumab: an evidence-based review of its potential in the treatment of moderate-to-severe psoriasis | Core Evidence | 2014 | 21 |
| 35 | Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy | Core Evidence | 2015 | 21 |
| 36 | Donepezil in Alzheimer's disease: an evidence-based review of its impact on clinical and economic outcomes | Core Evidence | 2006 | 21 |
| 37 | Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation | Core Evidence | 2010 | 20 |
| 38 | Conivaptan: Evidence supporting its therapeutic use in hyponatremia | Core Evidence | 2009 | 20 |
| 39 | Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer | Core Evidence | 2014 | 20 |
| 40 | Azilsartan medoxomil in the management of hypertension: an evidence-based review of its place in therapy | Core Evidence | 2016 | 20 |
| 41 | Enasidenib in the treatment of relapsed/refractory acute myeloid leukemia: an evidence-based review of its place in therapy | Core Evidence | 2019 | 20 |
| 42 | Pitavastatin: evidence for its place in treatment of hypercholesterolemia | Core Evidence | 2010 | 19 |
| 43 | Colesevelam hydrochloride: evidence for its use in the treatment of hypercholesterolemia and type 2 diabetes mellitus with insights into mechanism of action | Core Evidence | 2012 | 19 |
| 44 | Dulaglutide: an evidence-based review of its potential in the treatment of type 2 diabetes | Core Evidence | 2015 | 19 |
| 45 | Eslicarbazepine acetate in the treatment of adults with partial-onset epilepsy: an evidence-based review of efficacy, safety and place in therapy | Core Evidence | 2018 | 19 |
| 46 | Hypofractionated external-beam radiation therapy (HEBRT) versus conventional external-beam radiation (CEBRT) in patients with localized prostate cancer: a systematic review and meta-analysis | Core Evidence | 2013 | 18 |
| 47 | Micafungin: an evidence-based review of its place in therapy | Core Evidence | 2014 | 18 |
| 48 | Palonosetron in the prevention of chemotherapy-induced nausea and vomiting: an evidence-based review of safety, efficacy, and place in therapy | Core Evidence | 2015 | 18 |
| 49 | Iloperidone in the treatment of schizophrenia: an evidence-based review of its place in therapy | Core Evidence | 2016 | 18 |
| 50 | Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy | Core Evidence | 2010 | 18 |
